Abraxane Approved For Treatment of Pancreatic Cancer

The FDA recently approved Abraxane for the treatment of metastatic pancreatic cancer. This is a breakthrough for Celgene (who acquired the drug with their acquisition of Abraxis), and is the first significant change in the treatment of pancreatic cancer in the last 8 years.  Results from the latest clinical trials, revealed at this year’s ASCO meeting, highlighted the drugs ability to extend the lives of pancreatic cancer patients from 3 to 6 months.

Additional News


Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.


About aspenbio

I write software for scientists. I'm interested in Java/Groovy/Grails, the Semantic Web and Cancer Biology.
This entry was posted in pancreatic cancer and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s